Delivering Market-Responsive Capability for Early Phase and Advanced Clinical Development

The NIHR is taking decisive action to gain ground internationally in early-phase delivery, advancedmodalities. Hear plans to enhance our research delivery capability to execute the most advanced, complex and high-value commercial studies at pace—and to pivot that capability as science, pipelines and population need change. With a specific focus on early-phase and advanced modalities, vaccines and immune therapies, and oncology, learn how we are accelerating innovation and aligning our national research delivery capability to global drug-development trends and NHS unmet clinical need.